NEW YORK, NY / ACCESSWIRE / February 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) will present at the Goldman Sachs Industrials and Materials Conference Webcast on Friday, May 15. Chief Financial Officer Ray Young will present at 12:10 p.m. Eastern Time. ADM’s presentation will be webcast live at w…
First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Watch for ADM to pioneer biofuels, more carbon capture projects Heather Clancy Wed, 05/13/2020 - 02:57 Although decarbonization of industrial processes remains a big technical challenge, food processing and commodities giant Archer Daniels Midland rec…
A deflationary spiral but a bullish long-term trend in the stock.The addressable market for ADM continues to grow but little respect for the stock.ADM has a respectable earnings record.The stock is not expensive at below $36 per share.Long-term call options o…
(Bloomberg) -- The coronavirus pandemic keeping cars off the roads and shutting down America’s meat plants is clouding the outlook for some of the world’s largest agricultural commodities traders.That’s because the fallout of the deadly virus is creating a do…
EMERYVILLE, Calif., Feb. 20, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful.
EMERYVILLE, Calif., Feb. 19, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,.
The New Delhi railway station is the second busiest station in the country with a daily footfall of over 500,000 a day in normal times, but today was different
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) today reported financial results for the quarter ended March 31, 2020. “I’m extremely grateful to our 38,000 global colleagues, whose commitment, ingenuity and agility are powering ADM as we support the global food su…
Q1 2020 Adamas Pharmaceuticals Inc Earnings Call
At a press briefing in early April, New York Governor Andrew Cuomo held up a hospital-green N95 respiratory mask. He had just delivered the day’s updated Covid-19 fatality figures, a number exacerbated in New York and elsewhere by a national shortage of the m…
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) will present at the 15th annual BMO Capital Markets 2020 Global Farm to Market Conference on Wednesday, May 13. Juan Luciano, Chairman and CEO, and Vince Macciocchi, President, ADM Nutrition, will present at 9:20 a.m.…
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) announced today an additional $800,000 in donations to organizations focused on addressing needs during COVID-19, including food assistance, hunger relief, and local support to hospitals and first responders. “These a…
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
Adamas (ADMS) delivered earnings and revenue surprises of 6.74% and 0.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in people with Parkinson's disease (PD) receiving levodopa-based therapy at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (PAS-MDS), February 14-16, 2020 in Miami, Florida. “The data presented at this year’s MDS-PAS conference build upon the growing evidence that GOCOVRI can help improve good ON time in patients with PD who experience levodopa-induced dyskinesia,” said Jean Hubble, Vice President, Medical Affairs at Adamas.
Q4 2019 Adamas Pharmaceuticals Inc Earnings Call
A lot has changed about air travel since it went mainstream in the 1930s. On-board smoking, free-flowing booze, and five-star meals have given way to baggage fees, cramped seats, and mystery meat. Through all this change, one thing has stayed the same — the …
SÃO PAULO & CHICAGO--(BUSINESS WIRE)--Marfrig (B3:MRFG3 and Level 1 ADR: MRRTY) and ADM (NYSE: ADM) today announced an agreement to create PlantPlus Foods, a joint venture for the sale of plant-based food products across South American and North American mark…
PHILADELPHIA, March 23, 2020 -- Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS).
EMERYVILLE, Calif., April 27, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday,.
Adamas Pharmaceuticals, Inc. (ADMS) a company dedicated to developing and delivering medicines that make a clinically meaningful difference for people affected by neurological diseases, today announced the publication of final results from a two-year open-label study in Parkinson’s disease (PD) that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using GOCOVRI® (amantadine) extended-release capsules. The trial enrolled 223 patients, and results demonstrated that the treatment effect of GOCOVRI on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society‐Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS), Part IV, was maintained for at least two years.
- Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI®.
EMERYVILLE, Calif., May 08, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five.
CHICAGO--(BUSINESS WIRE)--ADM’s (NYSE: ADM) Board of Directors has declared a cash dividend of 36.0 cents per share on the company’s common stock. The dividend is payable on June 10, 2020, to shareholders of record on May 20, 2020. This is ADM’s 354th consecu…
A common vision for the future of the nation's energy grid involves homeowners selling unused power generated from rooftop solar panels to others in their communities, and working together to help ensure the reliability, resiliency, and security of the power …
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI® (amantadine) extended release capsules. The new patent covers a method of reducing ‘OFF’ time and increasing ‘good ON’ time (ON time without troublesome dyskinesia) in people with Parkinson’s disease (PD) being treated with levodopa. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) announced today commitments to reduce water intensity by 10 percent and achieve a 90 percent landfill diversion rate by 2035 as part of an aggressive plan to continue to reduce the company’s environmental footprint. T…
There's been a major selloff in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) shares in the week since it released its...
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.